Red Light Holland
- Company typePublic
- Founded2020
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Red Light Holland firmographics
Firmographics- Name
- Red Light Holland
- Legal name
- Red Light Holland
- Website
- https://redlight.co
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Red Light Holland industry classification
Industry- Product category
- Psychedelic Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Herbal & Botanical Supplements (CRADAGAD)
- akta.pro secondary industry
- Hemp & CBD Product Wholesale Distribution (CRAOAIAG)
Keywords
Where Red Light Holland is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices4 records
Markets served
Red Light Holland business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Psilocybin Truffle Sales: Production and sale of premium psilocybin truffles in the Netherlands' legal adult-use market through Red Light Rec brand. Revenue generated from direct consumer sales via iMicrodose.nl and distribution through smart shop retail partners.
- Mushroom Home Grow Kit Sales: Sale of grow-at-home mushroom kits through wholly owned subsidiary Happy Caps. Products distributed through major retail channels including Costco Canada (82+ stores), Safeway/Albertsons (123 stores), Urban Outfitters, and Longo's. B2B and DTC sales models.
- Pharmaceutical Drug Development: Revenue generation through licensing and supply agreements for PEX010 botanical psilocybin drug candidate to academic institutions and clinical research sites. The company supplies drug candidate to 80+ studies globally and pursues drug development toward commercialization.
- Wholesale Distribution: SR Wholesale B.V. generates revenue through distribution and export of truffles, CBD products, cannabis seeds, Smartshop items, Headshop products, and Growshop goods across the Netherlands and EU markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Microdosing Kit - Psilocybin Truffle Product |
| Unit Pricing | Pay-as-you-go | Happy Caps Mushroom Home Grow Kits |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels6 records
Red Light Holland product offering
Product offeringCore offering
Red Light Holland produces and distributes premium psilocybin truffles in the Netherlands legal adult-use market through its Red Light Rec brand and iMicrodose kits, and sells mushroom home grow kits through subsidiaries such as Happy Caps via major retail channels. Following its April 2026 acquisition of Filament Health, the company also develops and supplies pharmaceutical-grade natural psilocybin drug candidates, principally PEX010, to academic and clinical research institutions globally, supported by GMP-compliant manufacturing and 70+ patents.
Differentiator
Problem solved
Functional benefit
Brands
- SR Wholesale: Dutch company specialized in selection, distribution and export of Truffles, CBD products, cannabis seeds, Smartshop items, Headshop products, Growshop goods and Cannabis Bake House products
- Radix Motion
- Happy Caps
- iMicrodose
- Wisdom Truffle
- FarmCare
- MisterCap
- MiniChamp BV
Products and services
- PEX010 Botanical Psilocybin Drug Candidate Pharmaceutical-grade standardized natural psilocybin drug candidate produced by wholly owned subsidiary Filament Health, intended for academic and clinical research in psychedelic-assisted therapies and supplied under GMP-compliant manufacturing.
- iMicrodose Microdosing Kits Pre-packaged psilocybin truffle microdosing kits sold directly to adult consumers in the Netherlands legal adult-use market.
- Red Light Rec Premium Magic Truffles Premium psilocybin truffles supplied by Red Light Rec to smart shops and through iMicrodose.nl for the Netherlands legal adult-use market.
- Happy Caps Mushroom Home Grow Kits Urban gourmet grow-your-own mushroom kits, including the 2kg Mega Block, sold direct-to-consumer via HappyCaps.ca and through retail partners including Costco Canada and Safeway/Albertsons in North America.
- Wisdom Truffle Augmented reality companion figurine promoting positivity and responsible technology use, integrated with Red Light Holland's AR platform.
- Mistercap Mushroom Home Grow Kits
Quantifiable outcome
- 69% of cancer patients fell below clinical thresholds for anxiety and depression after second psilocybin treatment session with improvements sustained for 24 weeks
- +2 more outcomes
Companies that use Red Light Holland
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
Red Light Holland technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Red Light Holland partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Jaguar HealthcoreMagdalena Biosciences joint venture partnership with Jaguar Health developing coca leaf extract as prescription drug candidate for post-GLP-1 weight loss management. Jaguar disclosed Q1 2026 revenue of $20.2 million representing 816% growth year-over-year. Red Light holds interest through Filament Health acquisition.
- GHU Paris Psychiatrie & NeurosciencescoreFilament Health signed agreement to supply PEX010 botanical psilocybin drug candidate for KETAPSYCHECOG study, a randomized double-blinded cross-over trial comparing behavioral and neural effects of psilocybin and ketamine in healthy volunteers. Agreement adds France to Filament's expanding international clinical research footprint.
- UCSF (University of California San Francisco)coreFilament Health signed agreement to supply PEX010 botanical psilocybin drug candidate to UCSF for double-blind randomized clinical trial investigating psychedelics in healthy older adults with low well-being, examining biomarkers for preclinical Alzheimer's disease using EEG and MRI imaging. Part of Dr. Robin Carhart-Harris's Global Psychedelic Study.
- Allu TherapeuticscoreExpanded partnership with Allu Therapeutics in New Zealand by adding Filament Health as supplying affiliate under existing supply agreement. Introduced first GMP-compliant standardized microdose format of PEX010 botanical psilocybin drug candidate. Supports New Zealand's regulatory framework permitting authorized psychiatrists to prescribe psilocybin to treatment-resistant patients.
- University of British ColumbiacoreFilament Health shipped PEX010 botanical psilocybin drug candidate to UBC for clinical studies in palliative care, bipolar II depression, and healthy adult mechanism research. UBC study addresses understudied bipolar disorder population largely excluded from prior psychedelic clinical trials.
- Irvine LabscoreFDA-compliant, DEA-registered partner receiving psilocybin shipments from Netherlands facility under US Controlled Substances import permits. Second 5kg shipment received in November 2025. Supports R&D activities and manufacturing of microdosing psilocybin capsules.
- Filament Health Corp.coreRed Light Holland completed acquisition of Filament Health effective April 29, 2026, through statutory plan of arrangement under British Columbia law. Filament became a wholly owned subsidiary, adding GMP-certified manufacturing, 76 issued patents, Health Canada Dealer's License, and PEX010 botanical psilocybin drug candidate. Exchange ratio of 0.36634769 shares per Filament share, with former Filament shareholders holding approximately 30% of combined company.
- University of CalgarycoreRepeat shipments of PEX010 botanical psilocybin drug candidate to University of Calgary supporting multiple clinical trials including alcohol use disorder, post-concussion symptoms, and treatment-resistant depression. Growing demand for pharmaceutical-grade naturally-derived psilocybin.
- Arizona State UniversityminorPartnership with Arizona State University to support groundbreaking Psychedelic Genome Project (PGP) research study. Collaboration contributes to understanding of psychedelic compounds and genetics.
- Drug Science ConsortiumminorPartnership with Drug Science to analyze iMicroapp data and promote responsible regulations for psilocybin microdosing. CTIO presented research findings to Drug Science Consortium.
- Kala Bio (KALA)coreRed Light Holland engaged Kala Bio's Researgency.ai on-premises AI infrastructure platform to support clinical development of PEX010 botanical psilocybin drug candidate. The AI platform assists in planning, protocol optimization, and scenario modeling for regulated clinical trials. KALA positioned this as first deployment client targeting the $180+ billion AI-in-healthcare market.
- Younet AIcoreKala Bio signed Platform Development and Exclusive License Agreement with Younet AI (2624465 Ontario Inc.) to build and deploy Researgency.ai on-premises AI infrastructure platform for biotechnology industry, enabling biotech companies to leverage AI without surrendering control of proprietary biological data.
- Trailbridge Mushroom FarmsminorHappy Caps partnered with Trailbridge Mushroom Farms to expand mushroom home grow kit production in the USA, increasing manufacturing capacity for U.S. retail distribution.
- Happy Caps Mushroom FarmcoreRed Light Holland completed 80% acquisition of Happy Caps Mushroom Farm in Nova Scotia for $450,000 (shares and cash) to expand market reach and product offerings in grow-at-home mushroom kits with potential future expansion into Europe and functional mushroom products.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Red Light Holland competitors and assessment
Company assessmentBroad incumbents
- Canopy Growth Corporation: Large-scale Canadian cannabis company founded by Bruce Linton (now Red Light's Advisory Board Chairman). Analog for what a vertically integrated natural product platform looks like at scale, and a model for how capital cycles can play out in regulated botanicals.
Direct peers
- Filament Health: Natural psilocybin drug developer and now a wholly owned subsidiary of Red Light Holland. Pre-acquisition Filament was the closest direct comparable, supplying PEX010 to academic clinical trials and operating a GMP facility — essentially the pharmaceutical arm that now defines Red Light's pharma business.
- Compass Pathways: Clinical-stage psychedelic medicine company developing synthetic psilocybin therapy (COMP360) for treatment-resistant depression. Direct peer competing for the same clinical and regulatory beachhead with a different (synthetic) formulation strategy.
- Mind Medicine (MindMed): Psychedelic medicine biotech developing LSD and psilocybin-based therapies for mental health and addiction. Operates in the same pharmaceutical psychedelic category with a publicly listed clinical pipeline.
- ATAI Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for mental health indications. Competes in the same drug development space with a broader compound portfolio approach.
- Cybin Inc. Clinical-stage psychedelic therapeutics company developing psilocybin-based treatments for depression and addiction. Publicly listed peer with overlapping clinical indications and competing supply partnerships.
- GH Research: Clinical-stage biopharmaceutical company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparable psychedelic drug developer focused on pharmaceutical pathways.
Emerging players
- Numinus Wellness: Mental health company operating psychedelic-assisted therapy clinics and psilocybin research. Overlaps with Red Light's clinical footprint via compassionate access and clinic networks.
- Field Trip Health: Operator of ketamine-assisted psychotherapy clinics exploring psilocybin protocols. Adjacent clinical delivery model sharing mental health indications with PEX010's research programs.
- Jaguar Health: Commercial-stage plant-derived pharmaceutical company and joint venture partner with Red Light's Magdalena Biosciences for coca leaf extract development. Comparable botanical drug development approach and target indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks3 records
Key highlights6 records
Customer concentration
Red Light Holland social profiles
Digital presenceRed Light Holland financial estimates
Financial estimateRevenue estimate
Valuation estimate
Red Light Holland leadership team
Management profileNumber of profiles
Profiles16 records
Red Light Holland subsidiaries and ownership
Company hierarchySubsidiaries8 records
Red Light Holland funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Red Light Holland M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Red Light Holland
What does Red Light Holland do?
Red Light Holland produces and distributes premium psilocybin truffles in the Netherlands legal adult-use market through its Red Light Rec brand and iMicrodose kits, and sells mushroom home grow kits through subsidiaries such as Happy Caps via major retail channels. Following its April 2026 acquisition of Filament Health, the company also develops and supplies pharmaceutical-grade natural psilocybin drug candidates, principally PEX010, to academic and clinical research institutions globally, supported by GMP-compliant manufacturing and 70+ patents.
Is Red Light Holland a public or private company?
Red Light Holland is a public company. It is classified as public and is currently operating.
When was Red Light Holland founded?
Red Light Holland was founded in 2020. It employs 11 to 50 people.
Where is Red Light Holland based?
Red Light Holland is headquartered in Toronto, Canada, in the North America region.
How does Red Light Holland make money?
Four revenue lines are on record. Psilocybin Truffle Sales are the primary driver. The others are mushroom Home Grow Kit Sales, pharmaceutical Drug Development and wholesale Distribution.
Who are Red Light Holland's main competitors?
Canopy Growth Corporation is listed as a broad incumbent. Direct peers are Filament Health, Compass Pathways, Mind Medicine (MindMed), ATAI Life Sciences, Cybin Inc. and GH Research. Emerging players are Numinus Wellness, Field Trip Health and Jaguar Health.
Does Red Light Holland have an API?
No public API is recorded for Red Light Holland.
What industry is Red Light Holland in?
Red Light Holland's product category is Psychedelic Pharmaceuticals. Its primary akta.pro industry code is CRADAGAD, Herbal & Botanical Supplements, with a secondary code of CRAOAIAG, Hemp & CBD Product Wholesale Distribution. Its NAICS code is 325411 and its SIC code is 2833.